Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage

Exclusion Criteria

• •1. Definite evidence of secondary ICH, such as structural abnormality, brain aneurysm, brain tumor, use of thrombolytic drugs;
• •2. Allergy to tetracycline antibiotics;
• •3. Use of vitamin A derivatives or steroid therapy within the past 3 months;
• •4. Concomitant infection requiring antibiotic treatment at admission;
• •5. Planned surgical intervention;
• •6. Life expectancy of less than 6 months due to comorbid conditions;
• •7. Severe hepatic and renal dysfunction, or AST and/or ALT \>3 times the upper limit of reference range, or serum creatinine \>265 μmol/L (\> 3 mg/dL);
• •8. Bleeding tendency, including heparin use within the past 48 hours (APTT ≥ 35 s), oral warfarin (INR \> 2), platelet count \< 100 × 10⁹/L, or hereditary hemorrhagic diseases;
• •9. Known pregnancy or breastfeeding;
• •10. Patients being enrolled or having been enrolled in another clinical trial within the 3 months prior to this clinical trial;
• •11. A high likelihood that the patient will not adhere to the study treatment and follow-up regimen;
• •12. Patients unsuitable for enrollment in the clinical trial according to the investigator's discretion.